This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / AilsynBio, Dong-E-E-Jiao AI-TCM Partnership
Business partnership agreement

AilsynBio, Dong-E-E-Jiao AI-TCM Partnership

Analysis based on 8 articles · First reported Apr 10, 2026 · Last updated Apr 12, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership between AilsynBio and Dong-E-E-Jiao is expected to positively impact the biotechnology and pharmaceutical markets by accelerating drug discovery through AI and modernizing Traditional Chinese Medicine. This collaboration could lead to new product developments and enhanced market positions for both AilsynBio and Dong-E-E-Jiao, potentially influencing investor sentiment in related sectors.

biotechnology pharmaceuticals artificial intelligence
Event Summary

AilsynBio, an AI-driven drug discovery company, and Dong-E-E-Jiao Co., Ltd., a subsidiary of China Resources Pharmaceutical Group, signed an Innovative Project Cooperation Agreement at the China — Hong Kong Science Park. This partnership aims to integrate Artificial Intelligence with traditional medicine to empower biopharmaceutical innovation. The collaboration will focus on advancing AI-driven innovation in R&D, launching specialized research on Premature Ovarian Insufficiency (POI), and promoting cross-border fusion of biotechnology, AI, and traditional medicine. Key figures from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation, and University of Hong Kong witnessed the signing, highlighting the significance of this cross-sector and cross-regional initiative.

Entities Involved
priv
AilsynBio
AilsynBio, an AI-driven drug discovery company, signed a project cooperation agreement with Dong-E-E-Jiao Co., Ltd. to integrate AI with traditional medicine, aiming to accelerate biopharmaceutical R&D and explore new paradigms in healthcare.
Importance 90.0 Sentiment 70.0
stock
Dong-E-E-Jiao
Dong-E-E-Jiao Co., Ltd. signed a project cooperation agreement with AilsynBio to deepen the scientific value of its products, particularly Compound E-Jiao Syrup, and accelerate its brand upgrade through technological innovation in traditional Chinese medicine.
Importance 90.0 Sentiment 60.0
stock
China Resources Pharmaceutical Group
China Resources Pharmaceutical Group, as the parent company of Dong-E-E-Jiao, views this collaboration as a key initiative to advance the modernization of Traditional Chinese Medicine (TCM) through AI integration, leveraging resources from Mainland China and China — Hong Kong.
Importance 70.0 Sentiment 50.0
per
Chen Bo
Dr. Chen Bo, Chief Scientific Officer of China Resources Pharmaceutical Group, noted the collaboration's importance for modernizing Traditional Chinese Medicine.
Importance 20.0 Sentiment 0.0
per
Liang Zheng
Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, stated the cooperation would strengthen the scientific foundation of their products in women's health.
Importance 20.0 Sentiment 0.0
per
Pierre Wang
Mr. Pierre Wang, Managing Director of HKU Versitech Limited, expressed honor in witnessing the project cooperation, highlighting the translation of academic research into industrial applications.
Importance 20.0 Sentiment 0.0
loc
China — Hong Kong
Importance 0.0 Sentiment 0.0
cnt
China
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.